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Abstract
Introduction: Serum interleukin (IL)-17 concentrations have been reported to be increased in systemic lupus
erythematosus (SLE), but associations with clinical characteristics are not well understood. We characterized clinical
associations of serum IL-17 in SLE.
Methods: We quantified IL-17 in serum samples from 98 SLE patients studied cross-sectionally, and in 246 samples
from 75 of these patients followed longitudinally over two years. Disease activity was recorded using the SLE
Disease Activity Index (SLEDAI)-2k. Serum IL-6, migration inhibitory factor (MIF), and B cell activating factor of the
tumour necrosis factor family (BAFF) were also measured in these samples.
Results: Serum IL-17 levels were significantly higher in SLE patients compared to healthy donors (P <0.0001). No
correlation was observed between serum IL-17 and SLEDAI-2k, at baseline or during longitudinal follow-up.
However, we observed that SLEDAI-2k was positively correlated with IL-17/IL-6 ratio. Serum IL-17 was significantly
increased in SLE patients with central nervous system (CNS) disease (P = 0.0298). A strong correlation was observed
between serum IL-17 and IL-6 (r = 0.62, P <0.0001), and this relationship was observed regardless of disease activity
and persisted when integrating cytokine levels over the period observed (r = 0.66, P <0.0001). A strong correlation
of serum IL-17 was also observed with serum BAFF (r = 0.64, P <0.0001), and MIF (r = 0.36, P = 0.0016).
Conclusions: Serum IL-17 concentration correlates poorly with SLE disease activity but is significantly elevated in
patients with CNS disease. IL-17/IL-6 ratio may be more useful than IL-17 or IL-6 alone to characterize Th17-driven
disease, such as SLE. The association of other cytokines with serum IL-17 suggests that IL-17 may drive activation of
diverse immune pathways in SLE.
Keywords: Autoimmunity, B cell activating factor of the tumour necrosis factor (TNF) family (BAFF), interleukin-6,
interleukin-17, macrophage migration inhibitory factor (MIF), systemic lupus erythematosus (SLE), T helper 17 (Th17)
Introduction
Systemic lupus erythematosus (SLE) is a chronic idio-
pathic systemic autoimmune disorder characterized by
multiple organ damage, particularly the joints, skin,
brain and kidneys [1]. This condition is characterized by
both innate and adaptive immune dysregulation
(reviewed in Vincent et al. [2]), but the relative impor-
tance of cytokines operative in these systems is
unknown. Interleukin (IL)-17 is the prototypic T helper
17 (Th17) cell pro-inflammatory cytokine. Since the
identification of Th17 cells as a third subset of CD4+ T
effector cells, [3,4] there has been much interest regard-
ing the role of the Th17 axis in the pathogenesis of
autoimmune disease. IL-17 has been associated with the
pathogenesis of a range of autoimmune diseases, includ-
ing rheumatoid arthritis (RA) [5], systemic sclerosis [6],
multiple sclerosis (MS) [7], and SLE [8]. IL-17 is recog-
nized to have a central role in lupus-prone mouse mod-
els [9,10] and therefore presumed to be involved in
human SLE pathogenesis (reviewed in Nalbandian et al.
[8]). Although not observed in all studies [6], serum IL-
17 levels have been found to be elevated in SLE patients
compared to controls [11-13]. Correlations between
serum IL-17 levels and SLE disease activity and anti-
double stranded DNA (anti-dsDNA) antibody levels
have previously been reported in some studies [11,13].
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However, research into the potential relationships
between IL-17 and the clinical expression of SLE has
been limited, and data from longitudinally followed
cohorts is lacking. Cytokines with diverse effects on the
immune system such as IL-6 [14-17], B cell activating
factor of the tumour necrosis factor family (BAFF), and
macrophage migration inhibitory factor (MIF) have each
been shown to have some interplay with IL-17 [18,19],
and to have potential roles in the pathogenesis or clini-
cal expression of SLE [2,20]. However, it is not clear
whether IL-17 regulates the expression of other cyto-
kines in patients with SLE.
In this study, we aimed to examine the associations
between serum IL-17 levels and disease expression in
SLE in terms of disease activity and organ involvement.
We also analysed the relationship between serum IL-17
levels and serum levels of IL-6, BAFF, and MIF. The
results indicate that although serum IL-17 levels do not
correlate with standard measures of disease activity, it is
increased in patients with CNS disease, and is strongly
associated with serum concentrations of IL-6, BAFF,
and MIF. Finally, our findings suggest that IL-17/IL-6
ratio may be a novel biomarker for disease activity in
SLE.
Material and methods
Patients and clinical assessments
Patients aged over 18 fulfilling the 1982 American Col-
lege of Rheumatology (ACR) criteria [21] for the classifi-
cation of SLE were recruited between May 2007 and
June 2009 from the Lupus Clinic of Monash Medical
Centre, Melbourne, Australia. Written informed consent
was obtained from each individual. Disease-related
damage was recorded at baseline using the Systemic
Lupus International Collaborating Clinics (SLICC) SLE
Damage Index (SDI) [22]. Other baseline variables col-
lected included patient age, gender, ethnicity and disease
duration. Disease activity was recorded at each clinic
visit using the SLE Disease Activity Index-2000 (SLE-
DAI-2k) [23]. Patients were recorded as having renal or
central nervous system (CNS) involvement if they had
evidence of involvement in ACR renal or CNS criteria,
or on any renal or CNS domains of the SLEDAI-2k or
SLICC-SDI at any time during the study period. Active
renal disease was defined as a non-zero score in any of
the renal components of the SLEDAI-2k. Patient follow-
up was as scheduled by the treating physician. Patients
received standard-of-care therapy. The Human Research
Ethics Committee, Southern Health, approved the study
protocol and materials.
Samples
Paired sera and SLEDAI-2k scores were collected from
patients at routine medical visits. Sera were stored at
-20°C until use. Measurements of C-reactive protein
(CRP), erythrocyte sedimentation rate (ESR), creatinine
and anti-dsDNA antibodies (Abs) titres (normal <7; Farr
assay, Anti-dsDNA kit, Trinity Biotech, Wicklow, Ire-
land), were performed. Healthy control samples were
obtains from the Australian Red Cross Blood Service.
Serum cytokine quantification
Sandwich enzyme-linked immunosorbent assay (ELISA)
was used to determine serum concentrations of IL-16,
IL-17, MIF, and BAFF. ELISA was performed using
R&D human IL-17 DuoSet ELISA development kit
(R&D Systems, Minneapolis, MN, USA). Ninety-six-well
ELISA plates (Immunoplates, Nunc, Roskilde, Denmark)
were coated with monoclonal mouse anti-human IL-17
antibody. Plates were blocked with 1% bovine serum
albumin in phosphate-buffered saline after overnight
incubation at 4°C. After washing, samples and standards
of recombinant human IL-17 were added to the plate
and incubated overnight. Biotinylated goat anti-human
IL-17 antibodies and streptavidin conjugated to horse-
radish peroxidase were used for detection, followed by
3,3’,5,5’- tetramethylbenzidine (Sigma-Aldrich, Sydney,
NSW, Australia) to develop colour. Plates were read at
450nm against standard curves for IL-17. The detection
limit of the assay was 16 pg/mL.
The above ELISA protocol was similarly completed
using the human IL-6 DuoSet ELISA development kit
(R&D Systems, Minneapolis, MN, USA). Similarly, MIF
concentrations were measured using mouse monoclonal
anti-human MIF antibodies (R&D Systems, Minneapolis,
MN, USA) for capture and goat biotinylated anti-human
MIF antibodies (R&D Systems, Minneapolis, MN, USA)
for detection. Recombinant human MIF was used as a
standard (R&D Systems, Minneapolis, MN, USA). 1%
bovine serum albumin in 5% sucrose-phosphate-buffered
saline was used as a blocking agent. For BAFF, a similar
ELISA protocol was performed, using purified mouse
anti-human BAFF antibodies (BD Biosciences, San Jose,
CA, USA) for coating the plates, and standards of
recombinant human BAFF (R&D Systems, Minneapolis,
MN, USA), and biotinylated goat anti-human BAFF
antibodies (R&D Systems, Minneapolis, MN, USA). The
detection limit of the assay was 1.5ng/ml. Each sample
was tested in duplicate.
Statistical analysis
Data are expressed as median and interquartile range
(IQR), except where otherwise indicated. As serum cyto-
kine concentrations were not normally distributed, non-
parametric analysis was used in this study. Spearman’s
rank test was used to analyze correlations between vari-
ables. Mann-Whitney U tests and chi-square tests were
used to compare groups of continuous and categorical
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data respectively. A P value of <0.05 was considered sta-
tistically significant. All tests were two-tailed unless
otherwise stated. Statistical analyses were performed
using GraphPad software (Prism Version 5.0D, 2010,
San Diego, CA, USA).
Results
Patient characteristics
A total of 343 paired sera and SLEDAI-2k scores were
collected from 98 SLE patients. The median (IQR) age
and disease duration at baseline were 40 (31 to 52)
years and 9 (4 to 15) years respectively. Thirty-nine
(39.9%) patients were Asian and 57 (58.2%) were Cauca-
sian. Baseline disease activity (n = 98) was highly vari-
able, with SLEDAI-2k scores ranging from 0 to 26, with
a median of 4. Seventy-five of these patients were stu-
died longitudinally on a total of between two and ten
occasions (median (IQR) number of visits = 3 (2 to 5);
median (IQR) time between visits = 12 (7 to 21) weeks).
Accordingly, time-adjusted means (TAM) were calcu-
lated for patients with more than one sample (n = 75).
Serum anti-dsDNA antibody levels correlated positively
with SLEDAI-2k (r = 0.43, P <0.0001) in this cohort, as
did SLICC-SDI scores with time-adjusted mean SLE-
DAI-2k (r = 0.24, P = 0.022) and disease duration (r =
0.51, P <0.0001) (data not shown). Twenty-nine (29.9%)
patients had CNS involvement. The majority (57.3%) of
patients were receiving prednisone or equivalent,
amongst whom the median (IQR) prednisone or equiva-
lent dosage was 5 (0 to 10) mg/day.
Associations between serum IL-17 and SLE disease
activity
We endeavoured to clarify the association of Th17 cyto-
kine measurement with SLE disease activity, taking the
advantage of cross-sectional and longitudinal follow-up
of these patients. At baseline, serum IL-17 was unde-
tectable in 39 patients, and concentrations were broadly
distributed, ranging from 0 to 3423 pg/ml. Baseline
median (IQR) serum IL-17 was 0 (0 to 63) pg/ml, and
mean (standard deviation) serum IL-17 was 140.6
(434.9) pg/ml. Serum IL-17 was undetectable in 37 of
39 healthy donors and their median (IQR) serum IL-17
was 0 (0 to 0) pg/ml. Serum IL-17 levels were signifi-
cantly higher in SLE patients compared to healthy
donors (P <0.0001). In SLE patients, there were no dif-
ferences in serum IL-17 concentration among SLE
patients according to ethnicity or gender. No correlation
was present between serum IL-17 levels and SLE disease
activity assessed by SLEDAI-2k, at baseline (Figure 1A).
There was no relationship between serum IL-17 and
anti-dsDNA antibodies, CRP, ESR, or prednisone
dosage, and there was no difference between patients
using or not using glucocorticoids (data not shown). In
samples separated categorically by disease activity, there
were no difference in serum IL-17 concentrations
between patients with inactive disease (SLEDAI-2k <4)
and those with active disease (SLEDAI-2k ≥4) or those
with higher levels of disease activity (SLEDAI-2k ≥8, 12,
16, or 18) (data not shown).
Figure 1 Association of serum IL-17 concentrations with disease
activity at a single point in time and over time. (A) Correlation of
serum IL-17 concentrations with SLEDAI-2k in SLE patients. No
significant correlations were observed. (B) Between-visit changes in
disease activity (delta SLEDAI-2k) was plotted against between-visit
changes in serum IL-17 concentrations (n = 246). No significant
correlations were observed. (C) SLEDAI-2k significantly correlated
with IL-17/IL-6 ratio in all samples, after removing both undetectable
IL-6 and IL-17. Serum IL-17 levels are expressed in pg/ml. IL-17,
interleukin-17; SLE, systemic lupus erythematosus; SLEDAI-2k, SLE
Disease Activity Index 2000.
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We next characterized relationships between change
in disease activity and change in serum IL-17 levels in
246 samples from 75 patients followed up on at least
one occasion after the first visit. In order to account for
differences in baseline between patients, we compared
changes in serum IL-17 levels (ΔIL-17) between conse-
cutive visits with corresponding changes in disease vari-
ables. There were no correlations between ΔIL-17 and
ΔSLEDAI-2k (Figure 1B), ΔESR, ΔCRP, Δanti-dsDNA
Abs, Δcreatinine or Δprednisone dosage (data not
shown). The adjusted mean SLEDAI (AMS) is a deriva-
tion of SLEDAI, calculated as the area under the curve
divided by the time observed, which allows the compari-
son between patients of variation in SLEDAI integrated
over time and has been shown to predict mortality
[24,25]. TAM serum IL-17 levels were calculated for the
75 patients with multiple samples. There was no rela-
tionship between AMS and TAM IL-17.
Associations between IL-17/IL-6 ratio and SLE disease
activity
Cell subset ratios relevant to Th17 activity, such as
Th17/regulatory T cells (Treg) ratio, Th17/Th1 cell
ratio or Th1/Th2 cell ratios, have been reported to exhi-
bit correlation with disease activity in autoimmune dis-
ease [26-29]. In the majority of such studies, ex vivo
cytokine production ratios were used to represent cell
populations [30]. Ratios of cytokine concentrations
within the same axis may also be a marker of immune
pathway activation, as has been reported for IL-17/TGF-
b ratio in schizophrenia or IL-17F/IL-22 ratio in chronic
hepatitis C virus infection [31,32]. We aimed to deter-
mine whether the ratio of IL-17 and IL-6, two major
cytokines involved in the Th17 pathway, could provide a
useful marker for disease activity in SLE. When
expressed as a ratio of IL-17 to IL-6 in the same patient,
SLEDAI-2k significantly correlated with IL-17/IL-6 ratio
in all samples, after removing those where both IL-6
and IL-17 were undetectable (r = 0.2712, P = 0.0131)
(Figure 1C).
Serum IL-17 association with the presence of CNS disease
in SLE
We also aimed to characterize the association of Th17
cytokine measurement with SLE expression in terms of
organ involvement. Serum IL-17 concentrations were
significantly increased in SLE patients with a history of
CNS disease (P = 0.0298) (Figure 2A). Similarly, TAM
IL-17 levels were increased in patients with CNS dis-
ease (P = 0.0495, one-tailed) (Figure 2B), and corre-
spondingly patients with TAM IL-17 levels above the
75th percentile had a higher prevalence of CNS disease
compared to the remaining patients (relative risk
(RR) = 2.0, 95% confidence interval (CI) 1.1 to 3.7).
In contrast, no change in serum IL-17 levels was
observed regardless of the presence or absence of renal
disease at baseline or in longitudinal follow-up (data
not shown). Of note, however, serum IL-17 concentra-
tion negatively correlated with creatinine levels (r =
-0.2836, P <0.0001) (data not shown). In the subgroup
of SLE patients with CNS disease, serum IL-17 levels
negatively correlated with prednisone dosage (r =
-0.247, P = 0.0066) (data not shown). In addition, in
the subgroup of CNS SLE patients, both of serum IL-6
and IL-17 levels were correlated with ESR (r = -0.208,
P = 0.0235, and r = -0.2501, P = 0.006, respectively)
(data not shown).
Figure 2 Association of serum IL-17 concentrations with the
presence of CNS disease in SLE patients. (A) Serum IL-17
concentrations in SLE patients with and without CNS involvement.
*P <0.05. (B) TAM serum IL-17 concentrations in SLE patients with
and without CNS involvement. *P <0.05. Serum IL-17 levels are
expressed in pg/ml. CNS, central nervous system; IL-17, interleukin-
17; SLE, systemic lupus erythematosus; TAM, time-adjusted mean.
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Correlation of serum IL-17 with other cytokines
Because of the potential of IL-17 to regulate other pro-
inflammatory cytokines, we analysed correlations
between serum IL-17 concentration and those of three
other cytokines associated with SLE. A strong positive
correlation was present between serum IL-6 and IL-17
levels both in the 98 baseline samples and when all sam-
ples were considered (r = 0.6508, P <0.0001; and r =
0.618, P <0.0001, respectively) (Figure 3A). This correla-
tion remained significant throughout all analysed subsets
of samples, including when samples with undetectable
IL-17 were excluded (r = 0.62, P <0.0001). The associa-
tion appeared independent of disease activity, as it was
similar in the subset of samples from patients with
active disease (SLEDAI-2k >4; r = 0.49, P <0.0001), and
with active renal disease (renal SLEDAI-2k >0; r = 0.50,
P <0.0001). This relationship also persisted over longitu-
dinal follow-up. TAM serum IL-6 levels correlated with
TAM serum IL-17 levels (r = 0.657, P <0.0001) (Figure
3B). We also measured changes in serum IL-6 (ΔIL-6)
and IL-17 (ΔIL-17) levels between visits. There was a
strong positive correlation between ΔIL-6 and ΔIL-17 (r
= 0.2542, P <0.0001) (Figure 3C).
A strong positive correlation was also observed
between serum IL-17 and serum BAFF levels in all sam-
ples (r = 0.64, P <0.0001) (Figure 4A). This remained
consistent through all analysed subsets of samples,
including samples with detectable levels of BAFF (r =
0.73, P <0.0001), samples from patients with active dis-
ease (SLEDAI-2k >4, r = 0.63, P <0.0001), and with
active renal disease (renal SLEDAI-2k >0, r = 0.75, P
<0.0001). TAM serum BAFF levels were also strongly
correlated with TAM serum IL-17 (r = 0.70, P <0.0001)
(Figure 4B). Whilst no significant correlation was pre-
sent between serum MIF and serum IL-17 when all
samples were analysed (data not shown), a positive
trend was present, and a positive correlation emerged
when samples without detectable levels of IL-17 were
removed from the analysis (n = 132, r = 0.36, P
<0.0001) (Figure 4C).
Discussion
The role of IL-17 in the pathogenesis of autoimmune dis-
eases is now well accepted, and as such, IL-17 is a poten-
tial therapeutic target. In this study, we report that serum
IL-17 levels were significantly elevated in the serum of
SLE patients compared to healthy controls, and among
SLE patients with CNS involvement compared to those
without. Moreover, we observed that IL-17/IL-6 ratio sig-
nificantly positively correlated with disease activity
assessed by SLEDAI-2k. We also report strong correla-
tions between serum levels of IL-17 and serum IL-6 and
BAFF, as well as a weaker, yet significant, correlation
between serum IL-17 and serum MIF. These results
suggest that these three cytokines may all potentially
interact with the Th17-mediated pathways and may be
involved with expression of IL-17-mediated inflammation
or conversely with the regulation of IL-17 production.
We found no correlation between SLEDAI-2k score
and serum levels of IL-17, IL-6, or MIF, as well as
Figure 3 Correlation of serum IL-17 concentrations with serum
IL-6 concentrations in SLE patients. (A) Correlation between serum
IL-6 and serum IL-17 levels in all samples. There was a strong positive
correlation (r = 0.618, P <0.0001). (B) Correlation between TAM serum
IL-6 and TAM serum IL-17 levels. There was a strong positive correlation
(r = 0.657, P <0.0001). (C) Correlation between changes in serum IL-6
(ΔIL-6) and IL-17 (ΔIL-17) levels between visits. There was a strong
positive correlation between ΔIL-6 and ΔIL-17 (r = 0.2542, P <0.0001).
Serum IL-6 and IL-17 levels are expressed in pg/ml. IL, interleukin; SLE,
systemic lupus erythematosus; TAM, time-adjusted mean.
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between ΔSLEDAI-2k and changes in these cytokines
levels, in any subset of our samples. Previous reports of
these relationships have been inconsistent. One publica-
tion reported a correlation between SLEDAI and serum
IL-17 [13], whilst another reported a correlation in only
patients without renal disease [11]. Conversely, other
studies showed no correlation in any patient subset
[33,34]. The reason for these discrepancies is unknown,
but may be partially attributable to the relatively small
sample sizes used in some studies. ELISA sensitivity as
well as uncontrolled confounding factors, such as immu-
nosuppressive medications, may influence serum cyto-
kine levels. Of note, SLE is a highly heterogeneous
disease, and it is likely that disease expression may differ
between different patient groups, especially regarding
major organ involvement, which may have impacted this
result. In addition, serum IL-17 levels may not be an
accurate reflection of total IL-17 production. IL-17 may
be localized to the inflamed tissue in some cases, such
as the brain, and therefore serum IL-17 levels may not
be a faithful reflection of its endogenous production.
However, we observed that SLEDAI-2k was significantly
positively correlated with IL-17/IL-6 ratio. Thus IL-17/
IL-6 ratio may more accurately characterize Th17-driven
disease than serum IL-17 or IL-6 alone. To the best of
our knowledge, this is the first published data that
reported correlation between SLE disease activity and
such a cytokine ratio.
As SLE is a highly heterogeneous disease, characteriz-
ing subgroups of SLE patients with specific disease phe-
notypes, such as major organ involvement, may improve
the investigation of SLE pathogenesis. Considering SLE
in terms of phenotypic subgroups may permit identifica-
tion of patients with pathogenic pathways that may be
amenable to targeted therapy. Cytokine measurement
may help to characterize these pathways, and to identify
potential therapeutic targets. In the current study,
serum IL-17 levels were significantly elevated in SLE
patients with CNS involvement. Our results suggest IL-
17 is involved in CNS SLE pathogenesis, and represents
a possible biomarker of CNS SLE and therapeutic target
in this subgroup. In this study, the percentage of indivi-
duals affected with CNS SLE was higher than in pre-
viously reported cohorts. Asian SLE patients had
significantly more history of CNS disease than Cauca-
sian SLE patients (P <0.05), and the high representation
of Asian ethnicity in this cohort may explain this differ-
ence. It would also be of interest to examine relation-
ships between serum IL-17 levels and CNS involvement
in relation to anti-phospholipid antibody status in future
studies. Recent data suggest that Th1 cells act to facili-
tate the entry of Th17 cells in the CNS, which mediates
the subsequent release of chemokines and recruitment
of other inflammatory cells [35]. Both IL-17 and IL-6
Figure 4 Correlation of serum IL-17 concentrations with both
serum BAFF and MIF concentrations in SLE patients. (A)
Correlation between serum IL-17 and serum BAFF levels in all
samples. A strong positive correlation was present (r = 0.64, P
<0.0001). (B) Correlation between TAM serum IL-17 levels and TAM
serum BAFF in all samples. A strong positive correlation was present
(r = 0.70, P <0.0001). (C) Correlation between serum IL-17 and
serum MIF (after removing undetectable IL-17 levels). A strong
positive correlation was present (n = 132, r = 0.36, P <0.0001).
Serum IL-17 levels are expressed in pg/ml. Serum BAFF and MIF
levels are expressed in ng/ml. BAFF, B cell activating factor of the
tumour necrosis factor family; IL, interleukin; MIF, macrophage
migration inhibitory factor; SLE, systemic lupus erythematosus; TAM,
time-adjusted mean.
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are highly expressed in MS lesions [7], and IL-17 is ele-
vated in the serum and cerebrospinal fluid (CSF) of
these patients [36]. An in vitro study has shown that
human Th17 cells may be well equipped to breach the
blood-brain barrier and infiltrate the CNS parenchyma
[37]. In addition, Cua et al. showed that IL-23p19-/-
mice characterized by an IL-17 deficiency, were resistant
to experimental autoimmune brain inflammation, sug-
gesting IL-23 (and thereby IL-17) as a crucial cytokine
in autoimmune CNS diseases [38]. Meyers et al. showed
that type I interferon (IFN) can inhibit IL-17 production
in human peripheral blood mononuclear cells (PBMCs),
suggesting a repressive effect of type I IFN on Th17
cells [39]. Studies investigating the relationship between
IL-17 and type I IFN in human SLE would be of inter-
est. Of note, IFN-gamma is also known to have a sup-
pressive effect on Th17 development (reviewed in Shah
et al. [40]). Shah et al. suggested that IL-17 production
by Th17 cells in SLE is the consequence of dysregula-
tion of Th17/Th1 balance [40]. Interestingly, Prado et
al. recently showed that Th17/Th1 ratio was increased
in SLE patients using glucocorticoids, compared to
healthy controls [27]. Such an effect was not supported
by our finding of equivalent serum IL-17 regardless of
corticosteroid use.
Immunosuppressant drugs used in SLE could also
impact on serum IL-17 concentrations, and thereby may
be a confounding factor when analysing correlation
between serum cytokines and disease activity. In our
study, there was no relationship between serum IL-17
and prednisone dosage, and there was no difference
between patients using or not using glucocorticoids.
Assessment of immunosuppressant drug effects on
serum IL-17 would be of interest; however, as we ana-
lysed patients followed for up to 10 serial visits, many
changes in drug therapy occurred in individual cases,
and together with variation in corticosteroid dose and
disease activity the data do not allow us to make useful
analyses of this question.
Clinical trials involving biologics targeting IL-17 are
currently under way in several immune diseases. Secuki-
numab (AIN457) is a fully human anti-IL-17A IgG1
monoclonal antibody (mAb), being studied in clinical
trials in psoriasis, RA, Crohn’s disease (CD), psoriatic
arthritis (PsA), ankylosing spondylitis and MS. Although
secukinumab was not effective in CD [41] and did not
meet the primary endpoint in a phase II clinical trial in
RA [42], it appears to be a promising therapy in phase
II clinical trials in psoriasis [43]. Ixekizumab
(LY2439821), a humanized IgG4 anti-IL17A mAb has
showed efficacy in phases I and II in RA [44] and psor-
iasis [45], respectively, and is currently being studied
in RA, PsA and psoriasis. Brodalumab (AMG 827), an
anti-IL-17R mAb, is also currently being studied in clin-
ical trials in RA, PsA, psoriasis, CD and asthma, with
clinical improvement in psoriasis in phase II [46]. At
present, no clinical trials of anti-IL-17 therapy are under
way in SLE. The current findings suggest that CNS dis-
ease may be a particular target group for anti-IL-17
therapy in SLE.
Although not previously reported, the strong correla-
tion found between serum IL-6 and IL-17 levels was in
line with expectations, as IL-6 is one of the inflammatory
cytokines required, in combination with TGF-b, for naïve
T cells to differentiate into Th17 cells (reviewed in Nal-
bandian et al. [8]). Prospective analysis of changes in
serum IL-6 and IL-17 concentrations in over 300 samples
is a strength of this study, and we found that changes in
serum IL-6 and IL-17 levels between visits were corre-
lated, as were TAM IL-6 and TAM IL-17. Other cyto-
kines such as IL-1b, TNF-a, IL-21, and IL-23 are also
essential for sustaining IL-17 production. Furthermore,
IL-17 has been shown to upregulate IL-6 production in
mice, suggesting that a positive feedback loop may oper-
ate between the Th17 cell pathway and IL-6 [47]. Dong
et al. recently showed that IL-17 can increase IL-6 in
PBMCs from lupus nephritis patients [48].
The observed relationship between MIF and IL-17 is
also interesting. MIF is an important cytokine in a vari-
ety of autoimmune diseases and in particular SLE. MIF
is a known activator and facilitator of extracellular sig-
nal-regulated protein kinase (ERK), and recent reports
suggest extracellular signal-regulated kinase (ERK) mito-
gen-activated protein kinase (MAPK) is involved in IL-
17 production [19,49]. It has recently been reported that
IL-17 as well as IL-6 and IL-23 production was downre-
gulated in the lymph nodes of MIF-deficient mice, sug-
gesting MIF plays a role in Th17 differentiation and IL-
17 production [50]. Whether MIF could also induce
and/or enhance IL-17 production has not been reported
in a human disease state. To our knowledge, this is the
first report suggesting such a relationship in SLE.
We observed that serum BAFF levels correlated with
IL-17, as well as TAM BAFF with TAM IL-17, suggest-
ing a relationship between the BAFF system and Th17
cells in human SLE. Indeed, one of the BAFF receptors,
BAFF-receptor (BAFF-R or BR3) is expressed on acti-
vated T cells and Tregs (reviewed in Vincent et al. [2]).
Dong et al. has shown that IL-17 increased IL-6 and
anti-dsDNA antibodies in supernatant of culture PBMCs
from lupus nephritis patients [48], suggesting a role for
IL-17 in human B cell activation [8]. Supporting this,
Hsu et al., showed that autoimmune BXD2 mice, which
spontaneously produce high IL-17 levels, develop less
germinal centre B cells as well as reduced humoral
responses when IL-17R is lacking [9]. In a recent study,
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it has been demonstrated that BAFF can affect Th17 cell
response in mice [51]. Using BAFF transgenic (BAFF-
Tg) and BAFF knockout (KO) mice, it was demon-
strated that BAFF drives Th17 cells induction and
increased IL-6R expression. Of note, CNS infiltration of
Th17 cells was reported to be higher in BAFF-Tg mice,
and lower in BAFF KO mice, with autoimmune brain
inflammation. In healthy humans, a correlation was
reported between circulating Th17 frequency and BAFF
levels as well as switched-memory B cells [52]. As, in
turn, IL-17 is associated with IL-6 expression, BAFF
may be a key inducer and stimulator of the IL-6/IL-17
loop in human SLE.
Conclusions
In summary, in our study SLE patients with CNS disease
had significantly upregulated IL-17 levels compared to
patients without CNS involvement, suggesting IL-17 as
a potential biomarker and therapeutic target in CNS
SLE. Our results demonstrate for the first time in SLE a
human correlate of previously published murine studies
demonstrating the relationships of IL-6, BAFF and MIF
with IL-17 production. These data increase support for
investigation of IL-17 as a therapeutic target in SLE.
Measurement of IL-17 in patients treated with anti-
BAFF monoclonal antibodies could illuminate these
relationships further.
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